Telix Investors Urged to Seek Lead Plaintiff Status Before Jan. 9 in Securities Class Action
Investors face a Jan. 9, 2026 deadline to seek lead-plaintiff status in early-stage securities suits over alleged misstatements tied to SEC and FDA setbacks.
Overview
- Notices from The Gross Law Firm, Bronstein, Levi & Korsinsky, Hagens Berman, The Law Offices of Frank R. Cruz, and Rosen invite Telix investors to come forward for the lead-plaintiff process.
- The putative class covers purchasers of Telix securities from February 21, 2025 through August 28, 2025, according to the filings.
- Complaints allege Telix overstated progress of prostate cancer therapeutic candidates and the reliability of third-party manufacturing and supply partners, rendering public statements misleading.
- Filings cite regulatory disclosures including an SEC subpoena in July 2025 and an FDA Complete Response Letter on August 28 related to Zircaix.
- Hagens Berman reports that the FDA cited CMC deficiencies and Form 483 observations at two partner sites and says Telix ADSs fell sharply, including a 21% drop after the final disclosure, while firms note no class has been certified and many offer contingency representation with no out-of-pocket fees.